Stem Cell Theranostics secures "freedom to operate" in IP deal with GE Healthcare

By Gareth Macdonald

- Last updated on GMT

Related tags Ge healthcare Stem cell

Stem Cell Theranostics' headquarters in California, US
Stem Cell Theranostics' headquarters in California, US
Stem Cell Theranostics has secured rights to the technology it uses to make cellular heart disease models for drug development through a deal with GE Healthcare.

Stem Cell Theranostics announced the sub-license with GE Healthcare last night, explaining that the agreement covers intellectual property (IP) needed to generate human cardiomyocyte models for preclinical drug development from induced pluripotent stem cells (iPS).

Spokeswoman Rachel Bolger told us the deal “ensures that we and our partners have the appropriate freedom to operate,” ​adding that the firm will use the GE Healthcare IP in combination with cells from a biobank operated by the Stanford Cardiovascular Institute.

Using this biobank, we are able to generate a library of cardiomyocytes disease models that harbour genetic mutations that cause hypertrophic cardiomyopathy, dilated cardiomyopathy and various channelopathies.

These patient-derived cardiomyocytes exhibit a variety of disease phenotypes including hypertrophy, contraction defects and arrhythmias, making them attractive disease models for drug efficacy and toxicity testing.

She added that: “While other organizations have commercialized normal cardiomyocytes, we are currently the only commercial company that is focusing on genetic disease models for heart failure.”

Sub license

The IP was originally developed by Geron.

GE Healthcare licensed it in 2009 according to a company spokeswoman who explained that: "In 2012 GE expanded this agreement obtaining exclusive global rights to Geron’s IP for the development and sale of cellular assays derived from iPS cells."

GE Healthcare licensed the same IP to Cellular Dynamics in 2012. 

IP licensing

Heart disease models developed by Stem Cell Theranostics are already being used by the firm for its internal drug development programmes and by partners seeking to identify novel disease mechanisms and drug targets Bolger said.

The GE license follows just four months after the firm signed a non-exclusive deal to access knowhow developed by IPS Academia Japan.

Like the new accord, the earlier agreement covered use of IP to generate drug discovery models from cells obtained from a biobank, specifically one operated by Kyoto University’s Center for iPS Cell Research and Application.

Related news

Show more

Related products

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more